Global Gamma Aminobutyric Acid Market

Gamma Aminobutyric Acid Comprehensive Study by Type (GABAA, GABAB), Application (Attention Deficit Hyperactivity Disorder, Psychiatric Disorders, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease, Memory Impairment, Other), Process (Chemical Synthesis, Biological Fermentation) Players and Region - Global Market Outlook to 2030

Gamma Aminobutyric Acid Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.32%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gamma Aminobutyric Acid
Gamma-Aminobutyric acid (GABA) are the inhibitory neurotransmitter that found in the central nervous system of mammals. These neurotransmitter used to reduce the activity of neurons to which it binds, thus used to control fear and anxiety when neuron are over excited. Gamma-Aminobutyric acid market is expected to mark significant growth over forecasted period owing to increasing consumers spending on treatment of neurological disorders and mental disorders. The major companies are adding more proven technologies systematically and strategically in Asia-Pacific countries as these countries are focused on fastest-growing verticals in the healthcare sector.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR5.32%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new product launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Vendors will contribute the maximum growth to Global Gamma Aminobutyric Acid market throughout the forecasted period. Established and emerging Vendors should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), Athena Drug Delivery Solutions (India), Biocodex (France), Elan Corporation (Ireland), Eli Lilly & Company (United States), H.LundBeck (Denmark), GlaxoSmithKline (United Kingdom), NovaDel Pharma (United States), Novartis (Switzerland) and OVATION Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Vendors which are also part of the research coverage are Osmotica Pharmaceutical (United States), Pfizer (United States), Sanofi-aventis (France), VIVUS (United States) and XenoPort (United States).

Segmentation Overview
AMA Research has segmented the market of Global Gamma Aminobutyric Acid market by Type (GABAA and GABAB), Application (Attention Deficit Hyperactivity Disorder, Psychiatric Disorders, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease, Memory Impairment and Other) and Region.



On the basis of geography, the market of Gamma Aminobutyric Acid has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Process, the sub-segment i.e. Chemical Synthesis will boost the Gamma Aminobutyric Acid market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase demand of Gamma Aminobutyric Acid at Asia-Pacific regions. and Value Oriented Consumers

Market Growth Drivers:
Increase in Aging Population Leads to Boost the Requirement Of Gamma Aminobutyric Acid Market. and Rise in Incidence of Neurological Disorders

Challenges:
Limitation Due to Treatment of Mental Disorders Anticipated to Challenge the Market.

Restraints:
Side Effects Associated Within Gamma Aminobutyric Acid. and Low Awareness Among the Customers.

Opportunities:
Rapid Applications for Relieving Injuries and Decreasing Body Fat. and Increased Funding by Governments and Private Organizations.

Market Leaders and their expansionary development strategies
In September 2023, Supernus Pharmaceuticals said it has agreed to acquire Biscayne Neurotherapeutics in a deal that adds a Phase I epilepsy candidate to the buyer’s pipeline of treatments for central nervous system disorders. The epilepsy candidate, which Supernus will rename SPN-817, uses a novel synthetic form of huperzine A, an acetyl cholinesterase inhibitor that according to the company has a novel mechanism of action and has shown anticonvulsant activity
In November 2023, NOW Launches Calm & Focus Featuring GABA and Zembrin Sceletium Tortuosum. The formulation is designed to offer consumers a rapid-onset cognitive support product which provides a sense of calm. The ingredient is considered to have tangible effects, with clinical studies suggesting that it begins working within a two-hour window, and it has been subject to studies confirming that it is safe to use daily for several months.


Key Target Audience
Gamma Aminobutyric Acid Manufacturers, Gamma Aminobutyric Acid Traders, End-Use Market Participants of Different Segments of Gamma Aminobutyric Acid, Government and Research Organizations, R&D Institutions and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • GABAA
  • GABAB
By Application
  • Attention Deficit Hyperactivity Disorder
  • Psychiatric Disorders
  • Alzheimer's Disease
  • Chronic Obstructive Pulmonary Disease
  • Memory Impairment
  • Other
By Process
  • Chemical Synthesis
  • Biological Fermentation

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Aging Population Leads to Boost the Requirement Of Gamma Aminobutyric Acid Market.
      • 3.2.2. Rise in Incidence of Neurological Disorders
    • 3.3. Market Challenges
      • 3.3.1. Limitation Due to Treatment of Mental Disorders Anticipated to Challenge the Market.
    • 3.4. Market Trends
      • 3.4.1. Increase demand of Gamma Aminobutyric Acid at Asia-Pacific regions.
      • 3.4.2. Value Oriented Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gamma Aminobutyric Acid, by Type, Application, Process and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gamma Aminobutyric Acid (Value)
      • 5.2.1. Global Gamma Aminobutyric Acid by: Type (Value)
        • 5.2.1.1. GABAA
        • 5.2.1.2. GABAB
      • 5.2.2. Global Gamma Aminobutyric Acid by: Application (Value)
        • 5.2.2.1. Attention Deficit Hyperactivity Disorder
        • 5.2.2.2. Psychiatric Disorders
        • 5.2.2.3. Alzheimer's Disease
        • 5.2.2.4. Chronic Obstructive Pulmonary Disease
        • 5.2.2.5. Memory Impairment
        • 5.2.2.6. Other
      • 5.2.3. Global Gamma Aminobutyric Acid by: Process (Value)
        • 5.2.3.1. Chemical Synthesis
        • 5.2.3.2. Biological Fermentation
      • 5.2.4. Global Gamma Aminobutyric Acid Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gamma Aminobutyric Acid (Price)
      • 5.3.1. Global Gamma Aminobutyric Acid by: Type (Price)
  • 6. Gamma Aminobutyric Acid: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Athena Drug Delivery Solutions (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biocodex (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Elan Corporation (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly & Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. H.LundBeck (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NovaDel Pharma (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. OVATION Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gamma Aminobutyric Acid Sale, by Type, Application, Process and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gamma Aminobutyric Acid (Value)
      • 7.2.1. Global Gamma Aminobutyric Acid by: Type (Value)
        • 7.2.1.1. GABAA
        • 7.2.1.2. GABAB
      • 7.2.2. Global Gamma Aminobutyric Acid by: Application (Value)
        • 7.2.2.1. Attention Deficit Hyperactivity Disorder
        • 7.2.2.2. Psychiatric Disorders
        • 7.2.2.3. Alzheimer's Disease
        • 7.2.2.4. Chronic Obstructive Pulmonary Disease
        • 7.2.2.5. Memory Impairment
        • 7.2.2.6. Other
      • 7.2.3. Global Gamma Aminobutyric Acid by: Process (Value)
        • 7.2.3.1. Chemical Synthesis
        • 7.2.3.2. Biological Fermentation
      • 7.2.4. Global Gamma Aminobutyric Acid Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gamma Aminobutyric Acid (Price)
      • 7.3.1. Global Gamma Aminobutyric Acid by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gamma Aminobutyric Acid: by Type(USD Million)
  • Table 2. Gamma Aminobutyric Acid GABAA , by Region USD Million (2018-2023)
  • Table 3. Gamma Aminobutyric Acid GABAB , by Region USD Million (2018-2023)
  • Table 4. Gamma Aminobutyric Acid: by Application(USD Million)
  • Table 5. Gamma Aminobutyric Acid Attention Deficit Hyperactivity Disorder , by Region USD Million (2018-2023)
  • Table 6. Gamma Aminobutyric Acid Psychiatric Disorders , by Region USD Million (2018-2023)
  • Table 7. Gamma Aminobutyric Acid Alzheimer's Disease , by Region USD Million (2018-2023)
  • Table 8. Gamma Aminobutyric Acid Chronic Obstructive Pulmonary Disease , by Region USD Million (2018-2023)
  • Table 9. Gamma Aminobutyric Acid Memory Impairment , by Region USD Million (2018-2023)
  • Table 10. Gamma Aminobutyric Acid Other , by Region USD Million (2018-2023)
  • Table 11. Gamma Aminobutyric Acid: by Process(USD Million)
  • Table 12. Gamma Aminobutyric Acid Chemical Synthesis , by Region USD Million (2018-2023)
  • Table 13. Gamma Aminobutyric Acid Biological Fermentation , by Region USD Million (2018-2023)
  • Table 14. South America Gamma Aminobutyric Acid, by Country USD Million (2018-2023)
  • Table 15. South America Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 16. South America Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 17. South America Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 18. Brazil Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 19. Brazil Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 20. Brazil Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 21. Argentina Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 22. Argentina Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 23. Argentina Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 24. Rest of South America Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 27. Asia Pacific Gamma Aminobutyric Acid, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 31. China Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 32. China Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 33. China Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 34. Japan Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 35. Japan Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 36. Japan Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 37. India Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 38. India Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 39. India Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 40. South Korea Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 41. South Korea Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 42. South Korea Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 43. Taiwan Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 44. Taiwan Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 45. Taiwan Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 46. Australia Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 47. Australia Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 48. Australia Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 52. Europe Gamma Aminobutyric Acid, by Country USD Million (2018-2023)
  • Table 53. Europe Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 54. Europe Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 55. Europe Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 56. Germany Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 57. Germany Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 58. Germany Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 59. France Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 60. France Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 61. France Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 62. Italy Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 63. Italy Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 64. Italy Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 65. United Kingdom Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 68. Netherlands Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 69. Netherlands Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 70. Netherlands Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 71. Rest of Europe Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 74. MEA Gamma Aminobutyric Acid, by Country USD Million (2018-2023)
  • Table 75. MEA Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 76. MEA Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 77. MEA Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 78. Middle East Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 79. Middle East Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 80. Middle East Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 81. Africa Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 82. Africa Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 83. Africa Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 84. North America Gamma Aminobutyric Acid, by Country USD Million (2018-2023)
  • Table 85. North America Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 86. North America Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 87. North America Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 88. United States Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 89. United States Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 90. United States Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 91. Canada Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 92. Canada Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 93. Canada Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 94. Mexico Gamma Aminobutyric Acid, by Type USD Million (2018-2023)
  • Table 95. Mexico Gamma Aminobutyric Acid, by Application USD Million (2018-2023)
  • Table 96. Mexico Gamma Aminobutyric Acid, by Process USD Million (2018-2023)
  • Table 97. Gamma Aminobutyric Acid: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Gamma Aminobutyric Acid: by Type(USD Million)
  • Table 109. Gamma Aminobutyric Acid GABAA , by Region USD Million (2025-2030)
  • Table 110. Gamma Aminobutyric Acid GABAB , by Region USD Million (2025-2030)
  • Table 111. Gamma Aminobutyric Acid: by Application(USD Million)
  • Table 112. Gamma Aminobutyric Acid Attention Deficit Hyperactivity Disorder , by Region USD Million (2025-2030)
  • Table 113. Gamma Aminobutyric Acid Psychiatric Disorders , by Region USD Million (2025-2030)
  • Table 114. Gamma Aminobutyric Acid Alzheimer's Disease , by Region USD Million (2025-2030)
  • Table 115. Gamma Aminobutyric Acid Chronic Obstructive Pulmonary Disease , by Region USD Million (2025-2030)
  • Table 116. Gamma Aminobutyric Acid Memory Impairment , by Region USD Million (2025-2030)
  • Table 117. Gamma Aminobutyric Acid Other , by Region USD Million (2025-2030)
  • Table 118. Gamma Aminobutyric Acid: by Process(USD Million)
  • Table 119. Gamma Aminobutyric Acid Chemical Synthesis , by Region USD Million (2025-2030)
  • Table 120. Gamma Aminobutyric Acid Biological Fermentation , by Region USD Million (2025-2030)
  • Table 121. South America Gamma Aminobutyric Acid, by Country USD Million (2025-2030)
  • Table 122. South America Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 123. South America Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 124. South America Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 125. Brazil Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 126. Brazil Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 127. Brazil Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 128. Argentina Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 129. Argentina Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 130. Argentina Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 131. Rest of South America Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 134. Asia Pacific Gamma Aminobutyric Acid, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 138. China Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 139. China Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 140. China Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 141. Japan Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 142. Japan Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 143. Japan Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 144. India Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 145. India Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 146. India Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 147. South Korea Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 148. South Korea Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 149. South Korea Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 150. Taiwan Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 151. Taiwan Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 152. Taiwan Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 153. Australia Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 154. Australia Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 155. Australia Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 159. Europe Gamma Aminobutyric Acid, by Country USD Million (2025-2030)
  • Table 160. Europe Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 161. Europe Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 162. Europe Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 163. Germany Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 164. Germany Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 165. Germany Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 166. France Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 167. France Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 168. France Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 169. Italy Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 170. Italy Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 171. Italy Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 172. United Kingdom Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 175. Netherlands Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 176. Netherlands Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 177. Netherlands Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 178. Rest of Europe Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 181. MEA Gamma Aminobutyric Acid, by Country USD Million (2025-2030)
  • Table 182. MEA Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 183. MEA Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 184. MEA Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 185. Middle East Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 186. Middle East Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 187. Middle East Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 188. Africa Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 189. Africa Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 190. Africa Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 191. North America Gamma Aminobutyric Acid, by Country USD Million (2025-2030)
  • Table 192. North America Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 193. North America Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 194. North America Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 195. United States Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 196. United States Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 197. United States Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 198. Canada Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 199. Canada Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 200. Canada Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 201. Mexico Gamma Aminobutyric Acid, by Type USD Million (2025-2030)
  • Table 202. Mexico Gamma Aminobutyric Acid, by Application USD Million (2025-2030)
  • Table 203. Mexico Gamma Aminobutyric Acid, by Process USD Million (2025-2030)
  • Table 204. Gamma Aminobutyric Acid: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gamma Aminobutyric Acid: by Type USD Million (2018-2023)
  • Figure 5. Global Gamma Aminobutyric Acid: by Application USD Million (2018-2023)
  • Figure 6. Global Gamma Aminobutyric Acid: by Process USD Million (2018-2023)
  • Figure 7. South America Gamma Aminobutyric Acid Share (%), by Country
  • Figure 8. Asia Pacific Gamma Aminobutyric Acid Share (%), by Country
  • Figure 9. Europe Gamma Aminobutyric Acid Share (%), by Country
  • Figure 10. MEA Gamma Aminobutyric Acid Share (%), by Country
  • Figure 11. North America Gamma Aminobutyric Acid Share (%), by Country
  • Figure 12. Global Gamma Aminobutyric Acid: by Type USD/Units (2018-2023)
  • Figure 13. Global Gamma Aminobutyric Acid share by Players 2023 (%)
  • Figure 14. Global Gamma Aminobutyric Acid share by Players (Top 3) 2023(%)
  • Figure 15. Global Gamma Aminobutyric Acid share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Athena Drug Delivery Solutions (India) Revenue, Net Income and Gross profit
  • Figure 20. Athena Drug Delivery Solutions (India) Revenue: by Geography 2023
  • Figure 21. Biocodex (France) Revenue, Net Income and Gross profit
  • Figure 22. Biocodex (France) Revenue: by Geography 2023
  • Figure 23. Elan Corporation (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Elan Corporation (Ireland) Revenue: by Geography 2023
  • Figure 25. Eli Lilly & Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly & Company (United States) Revenue: by Geography 2023
  • Figure 27. H.LundBeck (Denmark) Revenue, Net Income and Gross profit
  • Figure 28. H.LundBeck (Denmark) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 31. NovaDel Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 32. NovaDel Pharma (United States) Revenue: by Geography 2023
  • Figure 33. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 35. OVATION Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. OVATION Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 37. Global Gamma Aminobutyric Acid: by Type USD Million (2025-2030)
  • Figure 38. Global Gamma Aminobutyric Acid: by Application USD Million (2025-2030)
  • Figure 39. Global Gamma Aminobutyric Acid: by Process USD Million (2025-2030)
  • Figure 40. South America Gamma Aminobutyric Acid Share (%), by Country
  • Figure 41. Asia Pacific Gamma Aminobutyric Acid Share (%), by Country
  • Figure 42. Europe Gamma Aminobutyric Acid Share (%), by Country
  • Figure 43. MEA Gamma Aminobutyric Acid Share (%), by Country
  • Figure 44. North America Gamma Aminobutyric Acid Share (%), by Country
  • Figure 45. Global Gamma Aminobutyric Acid: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Athena Drug Delivery Solutions (India)
  • Biocodex (France)
  • Elan Corporation (Ireland)
  • Eli Lilly & Company (United States)
  • H.LundBeck (Denmark)
  • GlaxoSmithKline (United Kingdom)
  • NovaDel Pharma (United States)
  • Novartis (Switzerland)
  • OVATION Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Osmotica Pharmaceutical (United States) , Pfizer (United States) , Sanofi-aventis (France) , VIVUS (United States) , XenoPort (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 246 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gamma Aminobutyric Acid Market Quantitative research analysis
Global Gamma Aminobutyric Acid Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), Athena Drug Delivery Solutions (India), Biocodex (France), Elan Corporation (Ireland), Eli Lilly & Company (United States), H.LundBeck (Denmark), GlaxoSmithKline (United Kingdom), NovaDel Pharma (United States), Novartis (Switzerland) and OVATION Pharmaceuticals (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase demand of Gamma Aminobutyric Acid at Asia-Pacific regions. " is seen as one of major influencing trends for Gamma Aminobutyric Acid Market during projected period 2023-2030.
The Gamma Aminobutyric Acid market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gamma Aminobutyric Acid Market Report?

Have a Query? Click Here

Other Related Reports

Ginger Oleoresin Comprehensive Study by Application (Food Additives, Medicines, Personal Care Products, Flavors and Fragrances, Daily Chemicals), Components (Shogaol, Gingerol, Zingerone, Others), In...
$ 3450
Pentalide Comprehensive Study by End User (Cosmetic, Toiletries, Personal Care Products, Fine Fragrances, Alcohol, Others), Fragrance House (Big, Medium, Small), Flavor (Powdery Heliotropine, Musk &...
$ 3350
Piperacillin Sodium Comprehensive Study by Type (98% Purity Type, 95% Purity Type), Configuration (Piperacillin Sodium Sulbactam Sodium Injection 8:1, Piperacillin Sodium Sulbactam Sodium Injection 4...
$ 3450
Bay Leaf Oil Comprehensive Study by Type (Absolute, Concentrates, Blends), Application (Medical, Food Products, Cosmetics, Homecare), Distribution Channel (Online, Offline {Supermarket, Hypermarket, ...
$ 3450
Calcium Alginate  Comprehensive Study by Application (Pharmaceutical, Food & Beverage, Textile, Others), Category (High M, High G), Form (Raw Powder, Dressings, Others) Players and Region - Global Ma...
$ 3500
Speciality Chemical Comprehensive Study by Type (Food-Additives, Cosmetic Chemicals, Water Treatment Chemicals, Textile Chemicals, Paper & Pulp Chemicals, Oil Field Chemicals), Function (Chemical Syn...
$ 3750